Loading...
•
Mar 31, 2021
Cardiff Oncology Q1 2021 Earnings Report
Announced first quarter 2021 results, highlighting clinical development programs and financial performance.
Key Takeaways
Cardiff Oncology reported $125.6 million in cash, cash equivalents and short-term investments as of March 31, 2021. Total operating expenses were $5.5 million for the quarter, with a net loss attributable to common stockholders of $5.185 million, or $0.14 per share.
Advanced clinical development programs, leveraging onvansertib combination trials across multiple cancer indications.
KRAS-mutated metastatic colorectal cancer (mCRC) trial continues to generate consistent and encouraging data.
Phase 2 trial in pancreatic ductal adenocarcinoma (PDAC) has been activated.
Phase 2 trial in metastatic castrate-resistant prostate cancer (mCRPC) continues to demonstrate durable disease control.
Forward Guidance
Cardiff Oncology expects continued progression of clinical programs to drive increased value throughout 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...